Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer

NCT00434356 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00434356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00434356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2007
Completion date
Not reported
Enrollment
46 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer